A phase I clinical trial evaluating rituximab combined with IL-2 against B-cell non-Hodgkin’s lymphoma, revealed that addition of IL-2 to rituximab therapy was safe and resulted in NK cell accumulation and ADCC activity that correlated with the better responses.738 Type I IFN could also preactivate NK cells by activating their receptors. Here, IL2 is linked to B-cell non-Hodgkin lymphoma.